Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A user is seeking advice on where to order Spironolactone online due to delays with Thailand Pharmacy and receives a recommendation for InHousePharmacy, despite current delays. The user is from Europe and cannot obtain the medication through a doctor.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

The user received trichotest results indicating finasteride is ineffective for them, and they plan to use dutasteride mesotherapy and add cetirizine to minoxidil. They seek advice on incorporating dutasteride into their regimen.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

Noxidil from Zeemoreuncle appears legitimate based on a bleach test with oral minoxidil tablets. The test results showed an instant color change, suggesting the product's authenticity.

Pyrilutamide, a hair loss treatment, is undergoing clinical trials in China and may be available in a few years. Users discuss the possibility of obtaining it early through group buys and synthesis by labs.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

Chronostim is a hair treatment with separate day and night formulas containing ingredients like lauric acid, glycyrrhetinic acid, and piroctone olamine. Users discuss its effectiveness for hair loss.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

A pharmacy error resulted in a finasteride solution being 100 times stronger than prescribed, not 10,000 times as initially feared. OP is advised to contact the pharmacy to clarify the preparation before traveling.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

People are discussing various hair loss treatments, including finasteride, minoxidil, RU58841, and new potential treatments like vdphl01, ABS-201, and KX-826. Some express hope in future developments like hair cloning and CRISPR, while others emphasize acceptance and sticking with current treatments.

Creatine might speed up hair loss in those prone to male pattern baldness, possibly due to increased DHT levels. Some users experience no issues when using creatine with treatments like finasteride, minoxidil, or dutasteride.

PP405 is considered a potential alternative to minoxidil and finasteride, but its effectiveness and safety are still uncertain. Many users suggest sticking with proven treatments like finasteride and minoxidil due to the lack of long-term data on PP405.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.